Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthArizona Complete Health concomitant antidepressant…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.11

    Concomitant Antidepressant Treatment

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.11 alerts

    Get alerted when Policy AZ.CP.PMN.11 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity and prior authorization criteria for concomitant use of more than one antidepressant for members of Arizona Complete Health - Arizona Medicaid (AzCH-CCP). Applies to providers seeking approval for combinations such as two SSRIs, an SSRI with an SNRI, or two SNRIs.

    Policy Summary
    PayerArizona Complete Health
    PolicyConcomitant Antidepressant Treatment
    Policy CodePolicy AZ.CP.PMN.11
    Change Type1Q 2025 annual review — administrative updates (AHCCCS drug list reference added)
    Effective Date07.16
    Last ReviewFeb 9, 2023
    Next Review Date
    Key ActionSubmit prior authorization with supporting documentation for continued concomitant use beyond the automatic 60-day cross‑taper.
    SourceLink
    POLICY UPDATE CHANGES

    Added instruction to refer to current AHCCCS Drug List for preferred products.

    Removed reference to Care1st Health plan and logos.

    Removed reference to retired policy AZ.CP.PMN.53 Off- Label Use policy

    Converted to new template and added Dosage and Administration; Added Product availability; updated references; TCAs no longer reject as concomitant therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60cross‑taper auto approval days
    6initial approval (months)
    12continued approval (months)
    >=3required adequate trials
    ~15refs updated
    4TCA products listed

    Coverage Criteria for Concomitant Antidepressant Use

    Initial Therapy - Treatment Resistant Depression

    Covered when ALL of the following are met:

    ALL of the following

    • Member has a diagnosis of treatment resistant depression (TRD).
    • Documentation of adequate trials of at least three (3) individual antidepressants listed on the AHCCCS Behavioral Health Drug Lists, from at least two (2) different therapeutic classes, each for 4-6 weeks at maximum tolerated doses.
    • Failure of previous single-agent antidepressant trials is due to one of the following: inadequate response at maximum tolerated dose; adverse reaction(s); or breakthrough symptoms.
    • Appropriate clinical monitoring has been completed, including monitoring of target symptoms, adverse reactions (including but not limited to signs and symptoms of serotonin syndrome), adherence to treatment, suicide risk, heart rate, blood pressure and weight.
    • Approval duration: 6 months.

    Initial Therapy - Obsessive Compulsive Disorder

    Covered when ALL of the following are met:

    ALL of the following

    • Member has a diagnosis of obsessive compulsive disorder (OCD).
    • Documentation of adequate trials of at least three (3) individual antidepressants listed on the AHCCCS Behavioral Health Drug Lists, from at least two (2) different therapeutic classes, each for 4-6 weeks at maximum tolerated doses.
    • Failure of previous single-agent antidepressant trials is due to one of the following: inadequate response at maximum tolerated dose; adverse reaction(s); or breakthrough symptoms.
    • Appropriate clinical monitoring has been completed, including monitoring of target symptoms, adverse reactions (including but not limited to signs and symptoms of serotonin syndrome), adherence to treatment, suicide risk, heart rate, blood pressure and weight.

    Continued Therapy

    Continued therapy is authorized when ALL of the following are met:

    ALL of the following

    • Member is currently receiving the medication via a health plan affiliated with Centene Corporation or the member previously met initial approval criteria.
    • Documentation of positive response to therapy (for example, reduction in signs/symptoms).
    • Approval duration: 12 months.

    Coverage guidance

    Coverage guidance (provider and policy guidance):

    ALL of the following

    • Cross tapers will automatically be approved for 60 days; providers must submit a prior authorization request for continued concomitant use of any two (2) antidepressants beyond the 60-day cross-taper period.
    • Refer to the current AHCCCS Drug List for preferred products when selecting agents for therapy.
    • Excluded from this policy are tricyclic antidepressants (TCAs), trazodone, mirtazapine, and bupropion which are often used as adjunctive therapy with other agents including other antidepressants; these agents are addressed separately (see limitations/exclusions).
    • Members currently taking an MAOI are not covered for concomitant antidepressant therapy under this policy.
    • Diagnoses/indications not FDA-approved are not authorized under this policy unless there is sufficient documentation of efficacy and safety per the AHCCCS FFS Prior Authorization Guideline - Coverage of Off-Label Non-FDA Approved Indications; refer to that guideline and other evidence of coverage documents as applicable.

    Coding, Durations, and Dosage

    Codes presentmixed
    N/ANo CPT/HCPCS/ICD codes provided in this document segment.
    Adequate trial duration - inv-10
    Required trial duration4-6 weeks at maximum tolerated doses
    Context - Initial Approval (TRD)Evidence of adequate trials of >=3 individual antidepressants from >=2 therapeutic classes for 4-6 weeks at max tolerated doses is required
    Context - Initial Approval (OCD)Same 4-6 week adequate trial requirement applies to obsessive compulsive disorder prior to concomitant therapy
    Dosage strengths - inv-11
    Imipramine (Tofranil)Tablets: 10 mg, 25 mg, 50 mg; Capsules: 75 mg, 100 mg, 150 mg
    Nortriptyline (Pamelor)Capsules: 10 mg, 25 mg, 50 mg, 75 mg; Oral solution: 10 mg/5 mL

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required: Cross tapers will be automatically approved for up to 60 days. Continued concomitant use of two or more antidepressants beyond the 60‑day automatic cross‑taper period requires prior authorization. Providers must submit a PA request and supporting documentation for continued utilization.

    • Submit PA for concomitant use beyond 60 days
    • Include office notes, labs, and clinical rationale
    Documentation Required

    Documentation Requirements

    Documentation Required: Providers must submit documentation (including office chart notes and lab results) demonstrating the member meets all approval criteria. Documentation must include evidence the member was adherent to prior treatment regimens and that non‑response was not due to nonadherence. Include monitoring for adverse effects and appropriate safety checks.

    • Office chart notes documenting diagnosis, symptom monitoring, and treatment history

    Pharmacotherapy Options and Combinations

    Pharmacotherapy - Concomitant antidepressants

    Concomitant Antidepressants - Allowed Combinations: Concomitant use of more than one antidepressant (e.g., two SSRIs, an SSRI with an SNRI, or two SNRIs) is addressed for FDA‑approved indications such as Treatment Resistant Depression and Obsessive Compulsive Disorder; clinicians should consider agent-specific cardiac risks (QTc) and avoid combinations with MAOIs.

    Refer to Appendix B for cardiac monitoring and TCA guidance.

    Pharmacotherapy (antidepressant combinations/augmentation)

    Pharmacotherapy - Combinations/Augmentation: Clinical guidance and referenced practice guidelines (e.g., APA, STAR*D, CO-MED) support consideration of antidepressant combinations or augmentation strategies when prior adequate single-agent trials have failed; decisions should align with published practice guidelines and include appropriate safety monitoring.

    Definitions and Important Terms

    Definition - Serotonin Syndrome (inv-21)
    DefinitionSerotonin syndrome: condition that occurs when medications cause high levels of serotonin
    Mild symptomsShivering, diarrhea
    Severe symptomsMuscle rigidity, fever, seizures; can be fatal if not treated
    Definition - MAOI (inv-22)
    DefinitionMAOI: Monoamine Oxidase Inhibitors
    ExamplesNardil, Parnate, Eldepryl, Marplan
    NoteMembers taking MAOIs are excluded from concomitant antidepressant coverage per policy guidance

    Background

    This policy addresses concomitant antidepressant strategies including combinations of two selective serotonin reuptake inhibitors (two SSRIs), an SSRI with an SNRI, or two SNRIs. Its intent is to provide coverage guidance for carefully selected, monitored use of such combinations in treatment‑resistant cases—for example, treatment‑resistant depression and certain cases of obsessive‑compulsive disorder—after requirements such as adequate single‑agent trials, documented inadequate response or intolerance, and appropriate clinical monitoring have been met.

    Revision History and Policy Changes

    2025-01-01annual_reviewLatest

    1Q 2025 annual review: added instruction to refer to the current AHCCCS Drug List for preferred products; removed references to Care1st Health plan and logos; removed reference to retired policy AZ.CP.PMN.53 and added AHCCCS FFS Prior Authorization Guideline for off-label non‑FDA indications.

    2018-01-01format_and_content_update

    Converted to new template and added Dosage and Administration, product availability, updated references, and changed handling of tricyclic antidepressants (no longer automatic rejection as concomitant therapy).

    Policy Summary
    PayerArizona Complete Health
    PolicyConcomitant Antidepressant Treatment
    Policy CodePolicy AZ.CP.PMN.11
    Change Type1Q 2025 annual review — administrative updates (AHCCCS drug list reference added)
    Effective Date07.16
    Last ReviewFeb 9, 2023
    Next Review Date
    Key ActionSubmit prior authorization with supporting documentation for continued concomitant use beyond the automatic 60-day cross‑taper.
    SourceLink
    On This Page
    Coverage Criteria for Concomitant Antidepressant UseCoding, Durations, and DosageProvider Requirements and Prior AuthorizationPharmacotherapy Options and CombinationsDefinitions and Important TermsBackgroundRevision History and Policy Changes
    Approval duration: 6 months.
  1. Members on medication combinations, doses, or for identified indications that do not meet published practice guidelines or treatment protocols, or on regimens without adequate safeguards/monitoring, are not authorized under this policy.
  2. When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid provisions take precedence; refer to the state Medicaid manual for applicable coverage provisions.
  3. Protriptyline (Vivactil)Tablets: 5 mg, 10 mg
    TrimipramineCapsules: 25 mg, 50 mg, 100 mg
  4. Laboratory results and monitoring relevant to safety
  5. Documentation of adherence and rationale for combination therapy
  6. Step Therapy

    Required Prior Medication Trials

    Required Prior Medication Trials: For initial approval, provide evidence of adequate trials of at least three (3) individual antidepressants from at least two (2) different therapeutic classes, each trial for 4–6 weeks at maximum tolerated doses, as listed on the AHCCCS Behavioral Health Drug Lists. For Obsessive Compulsive Disorder, the same requirement of ≥3 trials from ≥2 classes applies.

    • Document trials of ≥3 individual antidepressants from ≥2 classes
    • Each trial: 4–6 weeks at maximum tolerated dose
    • List drugs per current AHCCCS Behavioral Health Drug Lists
    Denial Risk

    Coverage Limitations / Denial Risk

    Coverage Limitations and Denial Risks: Coverage is not authorized for non‑FDA approved indications unless there is sufficient documentation per the AHCCCS FFS Prior Authorization Guideline for Off‑Label Use. Coverage is not authorized for members currently taking an MAOI, for medication combinations or regimens that do not meet published practice guidelines, or where significant polypharmacy or comorbidities create safety concerns. Members on regimens lacking adequate monitoring or safeguards may be denied.

    • Non‑FDA indications require off‑label PA documentation per AHCCCS FFS guideline
    • MAOI coadministration is not authorized
    • Regimens without guideline support or monitoring may be denied
    Note

    Refer to AHCCCS Drug List

    Refer to AHCCCS Drug List for Preferred Products: Providers must check the current AHCCCS Behavioral Health Drug List for preferred antidepressant products when documenting prior trials and selecting agents.

    • Verify preferred products on the current AHCCCS Drug List before submission
    Note

    Administrative Coverage Notes

    Administrative and Coverage Notes: Coverage decisions are subject to all terms, conditions, exclusions and limitations of the member’s coverage documents and applicable state and federal requirements. For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this clinical policy.

    • Coverage subject to plan contract, exclusions, limitations, and applicable laws
    • State Medicaid provisions override this policy where conflicting
    TCA product list and strengths - inv-23
    Imipramine (Tofranil)Tablets: 10, 25, 50 mg; Capsules: 75, 100, 150 mg
    Nortriptyline (Pamelor)Capsules: 10, 25, 50, 75 mg; Oral solution: 10 mg/5 mL
    Protriptyline (Vivactil)Tablets: 5, 10 mg
    TrimipramineCapsules: 25, 50, 100 mg
    2025-01-01annual_reviewLatest

    1Q 2025 annual review: policy updated to instruct providers to refer to the current AHCCCS Drug List for preferred products; removed plan-specific logos and references and removed citation to retired off‑label use policy AZ.CP.PMN.53.